查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2013027

抗癌藥物市場：2026-2032 年全球市場預測，按藥物類型、給藥途徑、治療方法、癌症類型、最終用戶和分銷管道分類。

Cancer Drugs Market by Drug Type, Administration Route, Therapy Type, Cancer Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年癌症治療市場價值為1,720.6億美元，預計到2026年將成長至1,887.2億美元，複合年成長率為10.13%，到2032年將達到3,382.9億美元。

主要市場統計數據
基準年 2025 1720.6億美元
預計年份：2026年 1887.2億美元
預測年份 2032 3382.9億美元
複合年成長率 (%) 10.13%

我們將著眼於根本促進因素、新興創新和策略性產業挑戰，為癌症藥物分析奠定基礎。

癌症治療的發展極為複雜，需要紮實的理論基礎來概述腫瘤學領域的基本要素。對過往突破性進展的多方面理解，為解讀當前化療、標靶治療和免疫調節劑領域的進展提供了必要的背景知識。本文以歷史里程碑為基礎，闡述了不斷成長的研究經費、不斷完善的監管途徑以及以患者為中心的醫療模式如何相互交織，共同影響著當今的治療重點。

技術突破和不斷發展的患者照護模式正在推動癌症藥物研發發生決定性變革。

過去十年，腫瘤治療領域發生了翻天覆地的變化，這主要得益於免疫腫瘤學和分子標靶治療的突破性進展。查核點抑制劑重塑了多種癌症的治療流程，促使標準療法和聯合治療的重新設計。同時，嵌合體抗原受體T細胞療法也完成了從實驗性治療方法到商業性化應用的轉變，開啟了個人化免疫療法的新時代。

評估美國新加徵關稅對癌症治療供應鏈、價格趨勢和全球競爭平衡的影響。

美國於2025年初實施的新關稅為癌症治療價值鏈上的所有相關人員帶來了巨大挑戰。採購和分銷合作夥伴面臨關鍵活性藥物成分成本上漲的困境，這些成分均來自全球供應商，迫使他們重新評估製造地。近幾個月來，一些機構已採取應對措施，包括供應商多元化、投資近岸外包以及重新談判長期契約，以降低關稅風險並防止藥品供應中斷。

揭示藥物類別、給藥途徑、治療方法、癌症適應症、最終用戶畫像和分銷網路等方面的關鍵細分見解。

對治療分類及其子類別的詳細分析，能夠清楚揭示抗癌藥物市場的現狀。化療仍然是核心治療方法，其中烷化劑、抗代謝藥物和抗腫瘤抗生素在腫瘤清除方面各有其療效和安全性方面的考慮。除了傳統的細胞毒性藥物外，免疫治療領域也湧現了查核點抑制劑和CAR-T療法，所有這些療法都需要專門的給藥方案和病患監測。

探討美洲、歐洲、中東、非洲和亞太地區腫瘤市場的區域趨勢和差異化市場促進因素。

區域差異透過醫療基礎設施、監管環境和報銷機制的差異，影響癌症治療的部署和推廣。在美洲，成熟的專科藥局網路與大型研究中心相輔相成，推動了先進治療方法的廣泛應用。北美領先的醫療中心正與支付方合作，開發創新的報銷方案，在降低前期成本的同時，將治療效果與價值掛鉤。

揭示構成癌症藥物生態系統的主要企業的策略性舉措、合作計畫和創新組合。

為適應不斷變化的癌症治療格局，關鍵產業相關人員已重新評估其策略重點。領先的創新企業正增加對早期藥物研發專案和後期臨床試驗的投資，以建立廣泛的免疫腫瘤學產品線並實現產品組合多元化。生物技術公司與大型製藥公司之間的合作正在加速，從而實現風險分散，並透過轉授許可和共同開發契約授權合約利用彼此的專業知識。

為行業領導者提供策略挑戰和可操作的建議，以利用新興機會並應對腫瘤市場的複雜性。

產業領導者應優先考慮建構整合的研發框架，將藥物發現、轉化研究和臨床應用連接起來，以加速從概念到商業化的進程。建立一個匯集藥物化學、生物標記分析和監管框架等領域專業知識的跨職能卓越中心，可以簡化決策流程並縮短研發週期。同時，與診斷服務提供者建立策略夥伴關係，能夠共同開發伴隨檢測方法，從而最佳化個人化治療方案。

全面闡述支持癌症藥物研究的嚴格調查方法、資料收集方案和分析框架。

為確保分析的穩健性，本研究採用多方面的調查方法，整合了全面的二手資料研究、專家訪談以及嚴謹的資料三角驗證。透過對同行評審期刊、監管指南和臨床試驗註冊庫的廣泛文獻回顧，我們得以深入了解治療方法的進展。同時，我們也分析了專有資料庫和產業期刊，以掌握競爭格局和專利趨勢。

整合關鍵發現、產業影響和未來展望，以推動癌症治療創新持續進步。

本篇綜述整合了多項關鍵研究成果，重點闡述了免疫腫瘤學、精準醫療工具以及數位醫療融合領域的突破性進展如何共同重塑癌症治療模式。新貿易政策的累積影響凸顯了建立具有韌性的供應鏈和創新報銷策略的必要性，以保障患者獲得治療的機會並確保商業性可行性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按藥物類型分類的抗癌藥物市場

  • 化療
    • 烷化劑
    • 抗代謝物
    • 抗腫瘤抗生素
  • 荷爾蒙療法
  • 免疫療法
  • 分子標靶治療
    • 誘導細胞凋亡的藥物
    • 單株抗體
    • 蛋白酪氨酸激酶抑制劑（TKIs）

第9章：抗癌藥物市場依給藥途徑分類

  • 肌肉內部
  • 靜脈
  • 口服
  • 皮下

第10章：依治療方法分類的抗癌藥物市場

  • 聯合治療
  • 單藥治療

第11章：以癌症類型分類的抗癌藥物市場

  • 乳癌
  • 結腸癌
  • 肝癌
  • 肺癌
  • 胰臟癌
  • 攝護腺癌

第12章：抗癌藥物市場：依最終用戶分類

  • 門診部
  • 家庭醫療保健
  • 醫院和診所

第13章：抗癌藥物市場：依通路分類

  • 醫院藥房
  • 零售藥房

第14章：抗癌藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：抗癌藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：抗癌藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國抗癌藥物市場

第18章：中國抗癌藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Getwell Oncology Pvt Ltd
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Kite Pharma, Inc by Gilead Company
  • Medivir AB
  • Merck & Co., Inc.
  • Nammi Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-431B7BFFBF7B

The Cancer Drugs Market was valued at USD 172.06 billion in 2025 and is projected to grow to USD 188.72 billion in 2026, with a CAGR of 10.13%, reaching USD 338.29 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 172.06 billion
Estimated Year [2026] USD 188.72 billion
Forecast Year [2032] USD 338.29 billion
CAGR (%) 10.13%

Establishing the Foundation of Cancer Drug Analysis by Highlighting Fundamental Drivers, Emerging Innovations, and Strategic Industry Imperatives

The complexity of cancer drug development demands a well-grounded introduction that outlines the fundamental forces shaping the oncology therapeutic sphere. A nuanced understanding of past breakthroughs provides essential context for interpreting ongoing advancements in chemotherapies, targeted approaches, and immunomodulatory agents. Building from historical milestones, this introduction illuminates how intensified research funding, expanded regulatory pathways, and patient-centric care models converge to influence contemporary priorities.

Moreover, rapid technological evolution in molecular diagnostics and biomarker discovery has created new opportunities for precision oncology, driving collaboration among academic institutions, biotech startups, and established pharmaceutical developers. In this light, the introduction establishes a framework for how shifting regulatory paradigms-such as accelerated approval programs and adaptive licensing-facilitate the entry of innovative compounds while ensuring patient safety.

By setting the stage with key research enablers, stakeholder motivations, and cross-sector partnerships, this section underscores the dynamic environment in which oncology stakeholders operate. It paves the way for subsequent analysis of disruptive trends and market-shaping events, providing readers with a cohesive starting point to appreciate the deeper insights that follow.

Navigating the Pivotal Transformations in Oncology Drug Development Driven by Technological Breakthroughs and Evolving Patient Care Paradigms

Over the past decade, transformative shifts have redefined the oncology therapeutics landscape, driven by breakthroughs in immuno-oncology and molecularly targeted treatments. Checkpoint inhibitors have reshaped therapeutic algorithms across multiple cancer types, prompting redesigns of standard of care and combination regimens. Simultaneously, chimeric antigen receptor T cell therapies have crossed thresholds from experimental modalities to commercial realities, heralding a new era of personalized immunotherapy.

In parallel, the convergence of big data analytics and precision medicine tools has accelerated the identification of patient subpopulations most likely to benefit from specific interventions. This evolution has compelled industry leaders to integrate companion diagnostics into clinical development plans, fostering collaborative models between diagnostic and therapeutic stakeholders. Moreover, digital health platforms now support remote monitoring and real-time outcome tracking, enhancing trial efficiency and enabling adaptive trial designs that reduce development timelines.

As regulatory bodies refine frameworks for advanced therapies, the industry adapts by forging strategic alliances, expanding manufacturing capabilities, and integrating artificial intelligence for compound discovery. These advances underscore an ongoing paradigm shift that elevates efficacy, safety, and patient-centricity at the heart of oncology R&D.

Assessing the Ramifications of Newly Implemented United States Tariffs on Cancer Drug Supply Chains, Pricing Dynamics, and Global Competitive Equilibrium

The implementation of new United States tariffs in early 2025 has introduced significant headwinds for stakeholders across the cancer drug value chain. Procurement and distribution partners are facing increased costs for critical active pharmaceutical ingredients sourced from global suppliers, prompting a reassessment of manufacturing footprints. In recent months, several organizations have responded by diversifying supplier bases, investing in nearshoring initiatives, and renegotiating long-term contracts to mitigate tariff exposure and secure uninterrupted drug availability.

Furthermore, heightened import duties on specialized components have compelled pharmaceutical companies to adjust pricing frameworks, which in turn places pressure on reimbursement dialogues with payers. Payer panels and health technology assessment bodies are closely monitoring these cost adjustments, leading some manufacturers to pursue risk-sharing agreements and performance-based contracts to sustain market access.

Transitioning beyond immediate cost considerations, industry participants are also reevaluating supply chain resilience by integrating advanced analytics for demand forecasting and inventory management. These strategic shifts underscore the multifaceted impact of tariff introductions, demonstrating how regulatory trade actions can cascade through production, pricing, and patient access, ultimately reshaping competitive dynamics in oncology drug markets.

Unraveling Critical Segmentation Insights across Drug Classes, Administration Pathways, Therapy Modalities, Cancer Indications, End User Profiles, and Distribution Networks

Insight into the oncology drug market emerges clearly when dissecting therapeutic classes alongside their respective subcategories. Chemotherapy remains a cornerstone modality, with alkylating agents, antimetabolites, and antitumor antibiotics demonstrating differentiated efficacy profiles and safety considerations in tumor eradication. Beyond traditional cytotoxics, the immunotherapy cohort has introduced checkpoint inhibitors and CAR-T treatments, each requiring specialized administration protocols and patient monitoring.

Administration routes further refine market understanding by highlighting patient convenience and adherence factors. Intravenous infusions dominate hospital settings, whereas oral formulations offer greater flexibility for outpatient management and home healthcare delivery. Intramuscular and subcutaneous injections occupy niche roles in maintenance therapies and prophylactic regimens, reflecting a balance between therapeutic intent and patient experience.

Therapy type segmentation, distinguishing combination regimens from monotherapy approaches, reveals evolving clinical strategies aimed at overcoming resistance and enhancing synergistic effects. Cancer type delineation uncovers unique demand patterns across breast, colorectal, liver, lung, pancreatic, and prostate cancer cohorts, each presenting distinct molecular targets and treatment pathways.

End user segmentation clarifies distribution of care delivery, from hospitals and clinics as centralized hubs to ambulatory care centers and home healthcare solutions that prioritize patient comfort. Distribution channel analysis underscores the roles of hospital pharmacies in inpatient settings and retail pharmacies in broadening access for maintenance therapies.

Exploring Regional Dynamics and Differentiated Market Drivers across the Americas, Europe Middle East and Africa, and the Asia Pacific Oncology Landscapes

Regional landscapes shape the deployment and adoption of cancer therapeutics through variations in healthcare infrastructure, regulatory environments, and reimbursement mechanisms. In the Americas, well-established specialty pharmacy networks complement leading research centers, driving robust uptake of advanced therapies. North American centers of excellence collaborate with payers to structure innovative reimbursement schemes that mitigate upfront costs and link outcomes to value.

Moving eastward, the Europe, Middle East, and Africa region presents a tapestry of regulatory frameworks. While Western European nations lean on centralized approval pathways and stringent health technology assessments, Middle Eastern markets are investing heavily in oncology infrastructure and forging public-private partnerships to expand access. African markets continue to build foundational oncology programs, with an increasing focus on affordable generics and biosimilars to bridge treatment gaps.

Across the Asia-Pacific domain, diverse economies drive heterogenous demand patterns. Advanced markets such as Japan and Australia leverage strong R&D ecosystems and integrated care models, while emerging economies prioritize capacity building in oncology centers and localization of manufacturing. Regional harmonization efforts aim to streamline regulatory submissions, accelerating the entry of novel agents into clinical practice and supporting patient-centric care models.

Illuminating Strategic Moves, Collaborative Endeavors, and Innovation Portfolios of Leading Entities Shaping the Cancer Therapeutics Ecosystem

Key industry participants have recalibrated their strategic priorities to align with the evolving oncology therapeutic environment. Leading innovators have pursued expansive immuno-oncology pipelines, investing in both early-stage discovery programs and late-stage clinical trials to diversify their portfolios. Collaboration between biotechs and major pharmaceutical firms has accelerated, enabling sublicensing deals and co-development agreements that distribute risk and leverage complementary expertise.

Manufacturers with robust biologics infrastructure are expanding capacity for cell and gene therapies, preempting anticipated manufacturing bottlenecks. Simultaneously, the emergence of digital health partnerships has allowed select companies to integrate real-world evidence collection into their launch strategies, enhancing post-market value propositions. Players with global regulatory experience are optimizing dossier submissions to navigate complex approval pathways, particularly in regions adopting novel regulatory paradigms.

Smaller specialized firms are capitalizing on niche targets, forging alliances to secure co-marketing opportunities and expand trial networks. Across the competitive landscape, agility and scientific differentiation have emerged as critical differentiators, enabling companies to position their assets effectively against established standards of care and pipeline entrants.

Strategic Imperatives and Pragmatic Recommendations for Industry Leaders to Capitalize on Emerging Opportunities and Navigate Oncology Market Complexities

Industry leaders should prioritize integrated R&D frameworks that bridge discovery, translational research, and clinical application to accelerate the path from concept to commercialization. Establishing cross-functional centers of excellence that coalesce medicinal chemistry, biomarker analytics, and regulatory expertise can streamline decision making and reduce development timelines. In parallel, forging strategic alliances with diagnostics providers will enable the co-development of companion assays that bolster personalized treatment protocols.

To mitigate supply chain vulnerabilities exposed by recent trade policy shifts, organizations must diversify sourcing strategies and invest in advanced supply planning platforms. Scenario modeling and digital twins for logistics networks can empower procurement teams to anticipate disruptions and maintain consistent access to high-value active pharmaceutical ingredients. Moreover, engaging payers early to define outcome-based reimbursement frameworks will align commercial strategies with therapeutic value and ensure sustained market access.

Finally, embedding patient-centricity through digital support services and telehealth integration can enhance adherence, real-world data capture, and long-term outcomes tracking. By adopting these recommendations, industry players can fortify their competitive positioning and lead in delivering next-generation oncology treatments.

Comprehensive Elucidation of Rigorous Research Methodologies, Data Collection Protocols, and Analytical Frameworks Underpinning the Oncology Drug Study

This research employs a multifaceted methodology that integrates exhaustive secondary research, primary expert interviews, and rigorous data triangulation to ensure analytical robustness. Extensive literature reviews of peer-reviewed journals, regulatory guidelines, and clinical trial registries provided a foundational understanding of therapeutic advancements. Concurrently, proprietary databases and industry publications were analyzed to map competitive activity and patent landscapes.

Primary insights were garnered through structured interviews with senior executives, clinical investigators, and reimbursement specialists, yielding firsthand perspectives on pipeline strategies, market access barriers, and patient needs. Quantitative and qualitative findings were cross-validated through triangulation techniques, ensuring consistency across data sources and minimizing bias.

Furthermore, the study incorporated scenario analyses to examine the impact of policy shifts, such as tariff implementations, on production and distribution dynamics. Ethical adherence to data privacy and confidentiality standards was maintained throughout. The resulting framework synthesizes complex inputs into a coherent narrative, furnishing stakeholders with actionable intelligence underpinned by transparent methodologies.

Synthesis of Core Findings, Industry Implications, and Forward-Looking Perspectives to Propel Continued Advancements in Cancer Drug Innovation

In synthesizing the core findings, the review underscores how immuno-oncology breakthroughs, precision medicine tools, and digital health integrations collectively redefine the cancer treatment paradigm. The cumulative effects of new trade policies highlight the necessity for resilient supply chains and innovative reimbursement strategies to preserve patient access and commercial viability.

Segmentation analyses clarify nuanced demand drivers across therapeutic classes, administration modes, and care settings, while regional insights reveal differentiated growth enablers shaped by regulatory and infrastructure variances. The competitive landscape analysis illustrates that collaborative alliances and agile portfolio management are essential for maintaining differentiation in a crowded pipeline.

Looking forward, the interplay between scientific innovation, regulatory evolution, and patient-centric frameworks promises to sustain momentum in oncology drug development. Stakeholders who embrace integrated research models, engage with payers on value-based approaches, and invest in resilient operational infrastructures will be best positioned to deliver transformative therapies and secure long-term market leadership.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Drugs Market, by Drug Type

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Antimetabolites
    • 8.1.3. Antitumor Antibiotics
  • 8.2. Hormone Therapy
  • 8.3. Immunotherapy
  • 8.4. Targeted Therapy
    • 8.4.1. Apoptosis-inducing Drugs
    • 8.4.2. Monoclonal Antibodies
    • 8.4.3. Tyrosine Kinase Inhibitors (TKIs)

9. Cancer Drugs Market, by Administration Route

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Cancer Drugs Market, by Therapy Type

  • 10.1. Combination Therapy
  • 10.2. Monotherapy

11. Cancer Drugs Market, by Cancer Type

  • 11.1. Breast Cancer
  • 11.2. Colorectal Cancer
  • 11.3. Liver Cancer
  • 11.4. Lung Cancer
  • 11.5. Pancreatic Cancer
  • 11.6. Prostate Cancer

12. Cancer Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Home Healthcare
  • 12.3. Hospitals & Clinics

13. Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy

14. Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Drugs Market

18. China Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Astellas Pharma Inc
  • 19.8. AstraZeneca PLC
  • 19.9. Bayer AG
  • 19.10. BeiGene, Ltd.
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Daiichi Sankyo Company, Limited
  • 19.13. Dr. Reddy's Laboratories Ltd.
  • 19.14. Eli Lilly and Company
  • 19.15. F. Hoffmann-La Roche Ltd
  • 19.16. Fresenius Kabi AG
  • 19.17. Getwell Oncology Pvt Ltd
  • 19.18. GlaxoSmithKline plc
  • 19.19. Incyte Corporation
  • 19.20. Kite Pharma, Inc by Gilead Company
  • 19.21. Medivir AB
  • 19.22. Merck & Co., Inc.
  • 19.23. Nammi Therapeutics, Inc.
  • 19.24. Novartis AG
  • 19.25. Pfizer Inc.
  • 19.26. Sanofi S.A.
  • 19.27. Sun Pharmaceutical Industries Ltd.
  • 19.28. Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
  • 19.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)